The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Grandfather, 3-month-old granddaughter dead after violent dog attack Opinion: Why Marjorie ...
Steven Nickolas is a writer and has 10+ years of experience working as a consultant to retail and institutional investors. Charlene Rhinehart is a CPA , CFE, chair of an Illinois CPA Society committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback